Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

2021年12月24日 12:16:11 来自: (0)参与

New clinical trial data published today in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.1
The study met the primary endpoint, where 54% of patients had no visible pustules after a single dose of spesolimab, compared to 6% receiving placebo at week one. 1
Spesolimab has been granted Breakthrough Therapy Designation in China and USA.

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investigational treatment, significantly improved signs and symptoms of generalized pustular psoriasis (GPP) in patients experiencing a flare.1

GPP is a rare, life-threatening neutrophilic skin disease, which is distinct from plaque psoriasis. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).2,3,4 There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life5 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure and sepsis and even death.6

In the 12-week trial, 53 patients experiencing a GPP flare were treated with a single intravenous dose of spesolimab or placebo. Most patients at the outset of the trial had a high or very high density of pustules and impaired quality of life. Results after one week demonstrated that:

  • 54% of patients treated with spesolimab showed no visible pustules compared to 6% of those treated with placebo;
  • 43% of patients treated with spesolimab showed clear/almost clear skin compared to 11% of those in the placebo group.1

Pustular and skin clearance continued for the duration of the study. This clearance was accompanied by clinically significant improvements in quality of life and symptoms such as pain and fatigue, compared to placebo.1

Over the 12-week duration of the study, non-serious infections rates were higher in the spesolimab group compared with placebo, with no pattern regarding pathogen and affected organs. Two patients reported to have drug reactions with eosinophilia and systemic symptoms.

“With no approved treatments in the U.S. or E.U. for GPP flares, there is a significant unmet need for people with this distressing and painful skin condition, that often requires emergency care,” said Mark Lebwohl, MD, lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J. Waldman Department of Dermatology, New York. “These clinical trial results show that spesolimab has the potential to completely clear the skin of the signs and symptoms of a GPP flare after only one week, with sustained effect observed for up to 12 weeks.”

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the treatment of GPP, and Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares. This designation is for therapies treating serious or life-threatening conditions where early clinical evidence suggests a substantial improvement compared to existing treatments. The Chinese Regulatory Authority Centre for Drug Evaluation (CDE) also recently granted Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares.

“At Boehringer Ingelheim, we are committed to finding transformative therapies to help advance treatment for people who urgently need them,” said Dr Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, Boehringer Ingelheim. “The findings indicate that spesolimab may have a significant and positive impact on patients experiencing a GPP flare.”

The clinical program for spesolimab includes two other trials that are currently underway. First, the Effisayil-2 trial is designed to investigate spesolimab as a maintenance treatment to prevent the occurrence of GPP flares. The Effisayil-ON trial is an open label five-year extension study to investigate the longer term efficacy and safety of spesolimab in patents with GPP.7,8

Please click on the following link for ‘Notes to Editors’: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/spesolimab-phase-ii-data

相关新闻
凤凰网友:遗忘。Forgotten.
评论:你若使用美人儿计,我就将计就计

淘宝网友:、 素颜 Queen。
评论:现在每天吃的是草,可是挤出来的却是青春痘。

本网网友:紅塵悲歡惆悵
评论:看我不顺眼的人,能给您心里添堵,我真是舒坦。

猫扑网友:Curtain情歌
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

天猫网友:Originalぃ原点
评论:年轻时,记住是本事,中年后,忘掉是智慧。

腾讯网友:我忘了那個他
评论:从小就有一个敌人叫“别人家的小孩”。他不爱玩游戏,从来只知道学习。

网易网友:柔眸1  Demon
评论:女人=吃饭+睡觉+花钱 女人=猪+花钱 女人-花钱=猪 结论:女人不花钱等于猪!

搜狐网友:苏素/mmmmm
评论:天长地久、根本没有;海枯石烂、纯属扯蛋。

百度网友:⒈朵死亡花°
评论:想让一个人对你念念不忘的话,最好的办法就是向他借钱。

其它网友:识趣 Content つ
评论:真正能阻止离婚的婚姻法是:离婚后房子归国家!

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin